AbbVie 2022: Still immuneIssue Archives, October 2022, TherapeuticsAbbVie may have doubled in size since the Allergan acquisition, but nearly half the company’s revenue, and a large chunk of its potential future growth, are still coming from a familiar place. Read more October 11, 2022/by Joshua Slatko https://www.pharmalive.com/wp-content/uploads/2022/10/Skyrizi.jpg 576 864 Joshua Slatko https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Joshua Slatko2022-10-11 05:30:092022-10-05 10:30:05AbbVie 2022: Still immune